8-K: Regulus Therapeutics Announces Positive Topline Results for RGLS8429 in ADPKD Trial

Regulus Therapeutics reported positive topline results from the third cohort of its Phase 1b study of RGLS8429 for autosomal dominant polycystic kidney disease (ADPKD), showing a dose response and reduction in kidney volume.

Summary

• Regulus Therapeutics announced positive results from the third cohort of their Phase 1b trial for RGLS8429, a treatment for autosomal dominant polycystic kidney disease (ADPKD).
• The study is a double-blind, placebo-controlled trial assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of RGLS8429 in adult ADPKD patients.
• The trial evaluated different weight-based and fixed doses, measuring changes in urinary polycystins 1 and 2 (PC1 and PC2), total kidney volume (htTKV), cyst architecture, and overall kidney function.
• The third cohort involved 16 subjects randomized to receive either 3 mg/kg of RGLS8429 or a placebo every other week for three months.
• RGLS8429 was well-tolerated with no safety concerns reported in the third cohort.
• The 3 mg/kg dose showed more consistent increases in PC1 and PC2 across patients compared to earlier cohorts.
• A dose response was observed across all doses tested, with statistical significance at 3 mg/kg compared to placebo.
• Exploratory MRI analysis suggested a reduction in htTKV at the 3 mg/kg dose after three months of dosing.
• 70% of subjects showed reductions in htTKV following the 3 mg/kg dose.
• Enrollment for the fourth cohort, which will include up to 30 patients, has commenced, with patients receiving an open-label fixed dose of 300 mg of RGLS8429 every other week for three months.

Sentiment

Score: 8

Explanation: The document presents positive topline results from a clinical trial, indicating progress in drug development. The positive data on PC1, PC2, and htTKV, along with good tolerability, contribute to a strong positive sentiment. However, the inherent risks in drug development temper the sentiment slightly.

Positives

• RGLS8429 showed a clear dose response, with the 3 mg/kg dose demonstrating statistically significant increases in PC1 and PC2.
• The drug was well-tolerated with no safety concerns reported.
• The study showed a reduction in htTKV in 70% of subjects at the 3 mg/kg dose, suggesting a positive impact on kidney volume.
• The initiation of the fourth cohort with an open-label fixed dose of 300 mg indicates continued progress in the clinical trial.

Risks

• The approach to drug discovery and development is novel and may not lead to marketable products.
• Preliminary or topline results are based on a preliminary analysis and may change after a more comprehensive review.
• Preclinical and clinical studies may not be successful.
• There are risks related to regulatory review and approval.
• The company relies on third-party collaborators and other third parties.
• There are risks related to intellectual property.
• The process of discovering, developing, and commercializing drugs is complex and carries inherent risks.
• Additional toxicology data may be negative.
• The company's ability to secure and deploy capital is a risk.

Future Outlook

The company is continuing its clinical trial with the initiation of the fourth cohort, which will evaluate a fixed dose of 300 mg of RGLS8429. The company will continue to assess the safety and efficacy of RGLS8429 and other pipeline programs.

Management Comments

• The company announced positive topline results from the third cohort of patients in its Phase 1b multiple-ascending dose (MAD) study of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD).

Industry Context

The announcement is significant in the context of the ongoing search for effective treatments for ADPKD, a genetic disorder with limited therapeutic options. The positive results from the Phase 1b trial suggest that RGLS8429 could be a promising candidate for further development.

Comparison to Industry Standards

• The results are promising compared to the current standard of care for ADPKD, which primarily focuses on managing symptoms and slowing disease progression.
• Other companies are also developing treatments for ADPKD, including Tolvaptan, which is approved for slowing kidney cyst growth, but RGLS8429's mechanism of action and early results suggest a potentially different approach.
• The observed reduction in htTKV is a key indicator of potential efficacy, and the 70% of subjects showing reductions is a positive signal compared to some other experimental therapies.
• Further studies will be needed to compare RGLS8429's efficacy and safety profile to other treatments in development.

Stakeholder Impact

• Shareholders may react positively to the positive clinical trial results.
• Patients with ADPKD may have increased hope for a new treatment option.
• Employees of Regulus Therapeutics may be motivated by the positive results.
• Potential collaborators and investors may be more interested in the company.

Next Steps

• The company will continue to enroll patients in the fourth cohort of the Phase 1b trial.
• The company will continue to analyze the data from the Phase 1b trial.
• The company will continue to develop RGLS8429 and other pipeline programs.

Key Dates

Keywords

RGLS8429, ADPKD, Autosomal Dominant Polycystic Kidney Disease, Phase 1b Trial, Clinical Trial, Polycystins, PC1, PC2, htTKV, Kidney Volume, Drug Development, Therapeutics